Muva nje, i-JYMed Technology Co., Ltd. imemezele ukuthi i-Leuprorelin Acetate, ekhiqizwa inkampani engaphansi kwayo i-Hubei JX Bio-Pharmaceutical Co., Ltd., iphumelele ngempumelelo ukuhlolwa kokubhaliswa kwezidakamizwa.
Ukubuka konke Kwemakethe Yezidakamizwa
I-Leuprorelin Acetate imithi ejovwayo esetshenziselwa ukwelapha izifo ezincike ku-hormone, ngefomula ye-molecular C59H84N16O12•xC2H4O2. I-gonadotropin-releasing hormone agonist (GnRHa) esebenza ngokuvimbela uhlelo lwe-pituitary-gonadal. Ekuqaleni wathuthukiswa ngabakwa-AbbVie kanye ne-Takeda Pharmaceutical, lo muthi uthengiswa ngaphansi kwamagama emikhiqizo ehlukene emazweni ahlukahlukene. E-United States, ithengiswa ngaphansi kwegama lomkhiqizo LUPRON DEPOT, kuyilapho e-China, imakethwa njenge-Yina Tong.
Sula Inqubo kanye Nezindima Ezichazwe Kahle
Kusukela ngo-2019 kuya ku-2022, ucwaningo nokuthuthukiswa kwemithi kwaqedwa, kwalandelwa ukubhaliswa kwe-API ngoMashi 2024, lapho isaziso sokwamukela sitholwa. Ukuhlolwa kokubhaliswa kwezidakamizwa kwaphasiswa ngo-Agasti 2024. I-JYMed Technology Co., Ltd. yayibophezelekile ekuthuthukisweni kwenqubo, ukuthuthukiswa kwendlela yokuhlaziya, izifundo zokungcola, ukuqinisekiswa kwesakhiwo, nokuqinisekisa indlela. I-Hubei JX Bio-Pharmaceutical Co., Ltd. ibiphethe ukukhiqizwa kokuqinisekiswa kwenqubo, ukuqinisekiswa kwendlela yokuhlaziya, kanye nezifundo zokuzinza ze-API.
Ukwandisa Imakethe kanye Nesidingo Esikhulayo
Izigameko ezikhulayo zomdlavuza wendlala yesinye kanye ne-uterine fibroids kuqhuba isidingo esikhulayo se-Leuprorelin Acetate. Imakethe yaseNyakatho Melika njengamanje iphethe imakethe ye-Leuprorelin Acetate, ngezindleko ezikhulayo zokunakekelwa kwempilo kanye nokwamukelwa okuphezulu kobuchwepheshe obusha okuyizisusa eziyinhloko zokukhula. Ngesikhathi esifanayo, imakethe yase-Asia, ikakhulukazi i-China, nayo ikhombisa isidingo esinamandla se-Leuprorelin Acetate. Ngenxa yokusebenza kahle kwawo, isidingo somhlaba wonke salo muthi siyanda, kanti usayizi wemakethe kulindeleke ukuthi ufinyelele ku-USD 3,946.1 million ngo-2031, okubonisa izinga lokukhula elihlanganisiwe lonyaka (CAGR) lika-4.86% ukusuka ngo-2021 kuya ku-2031.
Mayelana ne-JYMed
I-Shenzhen JYMed Technology Co., Ltd. (ngemuva kwalokhu ebizwa ngokuthi i-JYMed) yasungulwa ngo-2009, igxile ocwaningweni, ekuthuthukisweni, ekukhiqizeni nasekuthengisweni kwama-peptide nemikhiqizo ehlobene ne-peptide. Ngesikhungo esisodwa socwaningo kanye nezisekelo zokukhiqiza ezintathu ezinkulu, i-JYMed ingomunye wabakhiqizi abakhulu bama-API e-peptide ahlanganiswe ngamakhemikhali e-China. Ithimba eliyinhloko lenkampani le-R&D liziqhayisa iminyaka engaphezu kwengu-20 yesipiliyoni embonini ye-peptide futhi seliphumelele ukuhlolwa kwe-FDA kabili. Uhlelo lwe-JYMed lwezimboni ze-peptide olubanzi futhi olusebenzayo lunikeza amakhasimende uhla olugcwele lwezinsizakalo, okuhlanganisa ukuthuthukiswa nokukhiqizwa kwama-peptide okwelapha, ama-peptide ezilwane, ama-antimicrobial peptides, nama-cosmetic peptides, kanye nokubhaliswa nokusekelwa kokulawula.
Imisebenzi Yebhizinisi Eyinhloko
1.Ukubhaliswa kwasekhaya nokwamazwe ngamazwe kwe-peptide APIs
2.Amapeptide ezilwane nezimonyo
3.Ama-peptide angokwezifiso kanye nezinsizakalo ze-CRO, CMO, OEM
Izidakamizwa ze-4.PDC (i-peptide-radionuclide, i-molecule ye-peptide-encane, i-peptide-protein, i-peptide-RNA)
Ngokungeziwe ku-Leuprorelin Acetate, i-JYMed ithumele amafomu okubhalisa ku-FDA kanye ne-CDE kweminye imikhiqizo embalwa ye-API, okuhlanganisa nezidakamizwa ezidumile njengamanje zekilasi le-GLP-1RA njengeSemaglutide, Liraglutide ne-Tirzepatide. Amakhasimende azayo asebenzisa imikhiqizo ye-JYMed azokwazi ukubhekisela ngokuqondile inombolo yokubhalisa ye-CDE noma inombolo yefayela le-DMF lapho ethumela izicelo zokubhalisa ku-FDA noma ku-CDE. Lokhu kuzonciphisa kakhulu isikhathi esidingekayo sokulungiselela imibhalo yesicelo, kanye nesikhathi sokuhlola kanye nezindleko zokubuyekezwa komkhiqizo.
Xhumana nathi
I-Shenzhen JYMed Technology Co., Ltd.
Ikheli:8th&9th Floors, Building 1, Shenzhen Biomedical Innovation Industrial Park, No. 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen
Ucingo:+86 755-26612112
Iwebhusayithi:http://www.jymedtech.com/
Isikhathi sokuthumela: Aug-29-2024